Aware Super Pty Ltd as trustee of Aware Super Buys Shares of 284,836 Johnson & Johnson (NYSE:JNJ)

Aware Super Pty Ltd as trustee of Aware Super acquired a new stake in Johnson & Johnson (NYSE:JNJ - Free Report) in the 4th quarter, according to its most recent disclosure with the SEC. The fund acquired 284,836 shares of the company's stock, valued at approximately $41,193,000. Johnson & Johnson makes up about 0.7% of Aware Super Pty Ltd as trustee of Aware Super's portfolio, making the stock its 25th largest holding.

Several other institutional investors and hedge funds have also bought and sold shares of the company. Vanguard Group Inc. boosted its stake in shares of Johnson & Johnson by 0.8% in the 4th quarter. Vanguard Group Inc. now owns 232,792,559 shares of the company's stock valued at $33,666,460,000 after purchasing an additional 1,772,706 shares in the last quarter. Geode Capital Management LLC increased its holdings in Johnson & Johnson by 2.8% in the fourth quarter. Geode Capital Management LLC now owns 57,667,920 shares of the company's stock valued at $8,321,881,000 after purchasing an additional 1,561,036 shares during the period. Norges Bank acquired a new stake in shares of Johnson & Johnson in the fourth quarter valued at about $4,390,037,000. Wellington Management Group LLP raised its holdings in Johnson & Johnson by 1.8% during the 4th quarter. Wellington Management Group LLP now owns 24,356,572 shares of the company's stock worth $3,522,447,000 after purchasing an additional 431,205 shares during the last quarter. Finally, Invesco Ltd. raised its stake in Johnson & Johnson by 6.5% during the fourth quarter. Invesco Ltd. now owns 19,126,079 shares of the company's stock worth $2,766,014,000 after buying an additional 1,171,975 shares during the last quarter. Institutional investors own 69.55% of the company's stock.

Remove Ads

Johnson & Johnson Price Performance

NYSE:JNJ traded down $0.71 during trading hours on Tuesday, hitting $153.66. 10,723,823 shares of the company's stock traded hands, compared to its average volume of 7,973,461. The business's fifty day simple moving average is $159.39 and its two-hundred day simple moving average is $155.10. Johnson & Johnson has a 52 week low of $140.68 and a 52 week high of $169.99. The firm has a market cap of $370.29 billion, a P/E ratio of 23.11, a P/E/G ratio of 2.56 and a beta of 0.49. The company has a quick ratio of 0.86, a current ratio of 1.11 and a debt-to-equity ratio of 0.43.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last posted its quarterly earnings data on Tuesday, April 15th. The company reported $2.77 earnings per share for the quarter, beating the consensus estimate of $2.59 by $0.18. Johnson & Johnson had a net margin of 18.20% and a return on equity of 34.24%. The firm had revenue of $21.89 billion for the quarter, compared to analysts' expectations of $21.65 billion. On average, research analysts anticipate that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 10th. Stockholders of record on Tuesday, May 27th will be paid a dividend of $1.30 per share. This is a boost from Johnson & Johnson's previous quarterly dividend of $1.24. This represents a $5.20 dividend on an annualized basis and a dividend yield of 3.38%. Johnson & Johnson's dividend payout ratio (DPR) is 74.59%.

Wall Street Analyst Weigh In

Several equities analysts have issued reports on JNJ shares. Barclays boosted their price target on Johnson & Johnson from $159.00 to $166.00 and gave the company an "equal weight" rating in a research note on Tuesday, January 28th. The Goldman Sachs Group upgraded Johnson & Johnson from a "neutral" rating to a "buy" rating and lifted their price target for the company from $157.00 to $172.00 in a research note on Wednesday, April 9th. Guggenheim reiterated a "neutral" rating on shares of Johnson & Johnson in a research note on Wednesday, April 2nd. Argus raised Johnson & Johnson to a "strong-buy" rating in a research report on Friday, January 24th. Finally, Wells Fargo & Company reduced their price target on shares of Johnson & Johnson from $166.00 to $152.00 and set an "equal weight" rating for the company in a research report on Thursday, January 23rd. Eight investment analysts have rated the stock with a hold rating, nine have issued a buy rating and two have issued a strong buy rating to the stock. Based on data from MarketBeat, Johnson & Johnson has a consensus rating of "Moderate Buy" and an average price target of $171.50.

Insider Buying and Selling

In other Johnson & Johnson news, VP Robert J. Decker sold 6,999 shares of the company's stock in a transaction on Tuesday, February 25th. The shares were sold at an average price of $165.88, for a total value of $1,160,994.12. Following the completion of the transaction, the vice president now directly owns 21,001 shares in the company, valued at approximately $3,483,645.88. This represents a 25.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Timothy Schmid sold 403 shares of the company's stock in a transaction that occurred on Tuesday, February 18th. The stock was sold at an average price of $156.15, for a total value of $62,928.45. Following the transaction, the executive vice president now owns 15,098 shares in the company, valued at $2,357,552.70. This trade represents a 2.60 % decrease in their position. The disclosure for this sale can be found here. 0.16% of the stock is owned by corporate insiders.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.